Oseltamivir prescription and regulatory actions vis-à-vis abnormal behavior risk in Japan: Drug utilization study using a nationwide pharmacy database

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Urushihara, Hisashi ^a   Doi, Yuko ^b   Arai, Masaru ^c   Matsunaga, Toshiyuki ^c   Fujii, Yosuke ^b   Iino, Naoko ^d   Kawamura, Takashi ^a   Kawakami, Koji ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Ain Pharmaciez Inc   (Japan)

^c Kraft Inc   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; ZANAMIVIR; ANTIVIRUS AGENT;

ABNORMAL BEHAVIOR; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DATA BASE; DRUG CONTROL; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; INFANT; INFLUENZA; JAPAN; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; NEUROLOGIC DISEASE; PRESCRIPTION; RISK FACTOR; RISK REDUCTION; SCHOOL CHILD; TREND STUDY; BEHAVIOR; BEHAVIOR DISORDER; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG UTILIZATION; FACTUAL DATABASE; HIGH RISK BEHAVIOR; MEDICAL INFORMATION SYSTEM; PHARMACY; RETROSPECTIVE STUDY; RISK; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; BEHAVIOR; CHILD; CHILD BEHAVIOR DISORDERS; CLINICAL PHARMACY INFORMATION SYSTEMS; DATABASES, FACTUAL; DRUG UTILIZATION; HUMANS; INFLUENZA, HUMAN; JAPAN; OSELTAMIVIR; PHARMACIES; RETROSPECTIVE STUDIES; RISK; RISK-TAKING; TIME FACTORS; TREATMENT OUTCOME;

EID: 82755192487     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028483     Document Type: Article

References (34)

1. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, et al. (2006) Antivirals for influenza in healthy adults: systematic review. Lancet 367: 303-313.
2. Matheson NJ, Harnden AR, Perera R, Sheikh A, Symmonds-Abrahams M, (2007) Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev.
3. Satoh K, Nonaka R, Ogata A, Nakae D, Uehara S, (2007) Effects of oseltamivir phosphate (Tamiflu) and its metabolite (GS4071) on monoamine neurotransmission in the rat brain. Biol Pharm Bull 30: 1816-1818.
4. The Federation of Pharmaceutical Manufacturers' Associations of Japan (2004) Drug Safety Update No. 129, June 2004 [in Japanese] Tokyo, Japan.
5. Pharmaceuticals and Medical Devices Agency (2007) Regarding abnormal behaviors after Tamiful intake (Direction of issuance of a Dear Doctor letter), March 20, 2007 [in Japanese]. Tokyo, Japan.
6. The Federation of Pharmaceutical Manufacturers' Associations of Japan (2008) Drug Safety Update No. 166, January 2008 [in Japanese].Tokyo, Japan.
7. Jefferson T, Jones M, Doshi P, Del Mar C, (2009) Possible harms of oseltamivir-a call for urgent action. Lancet 374: 1312-1313.
8. Yorifuji T, Suzuki E, Tsuda T, (2009) Oseltamivir and abnormal behaviors: true or not? Epidemiology 20: 619-621.
9. Center for Drug Evaluation and Research (2005) Pediatric safety update for Tamiflu, Pediatric Advisory Committee meeting. 18 November 2005 Silver Spring, MD Food and Drug Administration.
10. Medicines and Healthcare Products Regulatory Agency (2010) Suspected Adverse Drug Reaction (ADR) Analysis, Influenza antivirals- oseltamivir (Tamiflu) and zanamivir (Relenza), February 4, 2010. London, UK.
11. Reaserch Division, Health Insurance Bureau (2010) Trend in Prescription Healthcare Cost, Fiscal Year 2008 [in Japanese]. Tokyo, Japan Ministry of Health, Labour and Welfare Available: http://www.mhlw.go.jp/bunya/iryouhoken/database/zenpan/cyouzai_doukou.html. Accessed April 5, 2010.
12. National Statistics Center (2008) Patient Survey, Portal Site of Official Statistics of Japan [in Japanese]. Statistics Bureau Ministry of Internal Affairs and Communications with the collaboration of Ministries and Agencies Available: http://www.e-stat.go.jp/SG1/estat/eStatTopPortal.do. Accessed January 5, 2010.
13. Chugai Pharmaceutical Co., Ltd. (2010) Tamiful® Package Insert, July 2010 [in Japanese]. 22 ed Tokyo, Japan.
14. GlaxoSmithKline KK, (2009) Relenza® Package Insert, October 2009 [in Japanese]. 12 ed Tokyo, Japan.
15. Infectious Disease Surveillance Center (2010) Sentinel Surveillance [in Japanese]. Tokyo, Japan Ministry of Health, Labour, and Welfare, National Institute of Infectious Diseases Available: http://idsc.nih.go.jp/idwr/ydata/report-Jb.html. Accessed June 5, 2010.
16. G-Search Limited (2010) G-SEARCH database [in Japanese]. Available: http://db.g-search.or.jp/. Accessed January 5, 2010.
17. Pharmaceuticals and Medical Devices Agency (2010) Information service website on pharmaceuticals and medical devices, Information on suspected adverse reaction cases reported to Pharmaceuticals and Medical Devices Agency [in Japanese]. Tokyo, Japan Available: http://www.info.pmda.go.jp/. Accessed January 5, 2010.
18. The Maintenance and Support Services Organization (2010) Medical Dictionary for Regulatory Activities. Available: http://www.meddramsso.com/index.asp. Accessed June 29, 2010.
19. Yokota S, (2006) Research report by the research group on occurence of influenza-associated complications, funded by the 2005 MHLW grants-in-aid [in Japanese]. Tokyo, Japan Ministry of Health, Labour, and Welfare.
20. Yoshida M, Matsui T, Ohkusa Y, Kobayashi J, Ohyama T, et al. (2009) Seasonal influenza surveillance using prescription data for anti-influenza medications. Jpn J Infect Dis 62: 233-235.
21. Nikkei Medical (2010) Value and clinical features of inhaled zanamivir: a questionnaire survey on anti-influenza drug use by Japan Physicians Association [in Japanese]. Nikkei Continuing Medical Education. Japan.
22. Weatherby LB, Walker AM, Fife D, Vervaet P, Klausner MA, (2001) Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of 'Dear Doctor' letters. Pharmacoepidemiol Drug Saf 10: 211-218.
23. Chugai Pharmaceutical Co, Ltd. (2009) The 15th periodic safety report on oseltamivir [in Japanese]. Tokyo, Japan.
24. Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N, (2007) Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 30: 891-898.
25. Morishima T, Togashi T, Yokota S, Okuno Y, Miyazaki C, et al. (2002) Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis 35: 512-517.
26. Subcommittee on Safety Measurement, Committee of Safety of Drugs, the Pharmaceutical Affairs and Food Sanitation Council (2009) The minutes of the first fiscal 2009 subcommittee on safety measurement regarding to oseltamivir phosphate (Tamiflu) held on June 16, 2009 [in Japanese]. Tokyo, Japan Ministry of Health, Labour and Welfare.
27. Nakamura K, Schwartz BS, Lindegardh N, Keh C, Guglielmo BJ, (2010) Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection. Clin Infect Dis 50: e47-49.
28. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, et al. (2001) Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20: 127-133.
29. Blumentals WA, Song X, (2007) The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons. MedGenMed 9: 23.
30. Smith JR, Sacks S, (2009) Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment. Int J Clin Pract 63: 596-605.
31. Toovey S, Rayner C, Prinssen E, Chu T, Donner B, et al. (2008) Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 31: 1097-1114.
32. Fujita T, Fujii Y, Watanabe Y, Osaka H, Wada T, et al. (2011) A Pharmacoepidemiologic Study on the Relationship between Neuropsychiatric Symptoms and Therapeutic Drugs after Infulenza Infection [in Japanese]. Jpn J Pharmacoepidemiol 15: 73-90.
33. Morgenstern H, (1998) Ecologic Studies. In: Rothman KJ, Greenland S, editors. Modern Epidemiology Second ed. Philadelphia Lippincott Williams & Wilkins.
34. Moore N, Hall G, Sturkenboom M, Mann R, Lagnaoui R, et al. (2003) Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 12: 271-281.